Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5643254 A
Publication typeGrant
Application numberUS 08/561,169
Publication dateJul 1, 1997
Filing dateNov 21, 1995
Priority dateMar 3, 1994
Fee statusPaid
Also published asCA2162117A1, CA2162117C, DE69534194D1, DE69534194T2, EP0696902A1, EP0696902A4, EP0696902B1, US5669905, WO1995023558A1
Publication number08561169, 561169, US 5643254 A, US 5643254A, US-A-5643254, US5643254 A, US5643254A
InventorsRonald W. Scheldrup, Laurent B. Schaller
Original AssigneeTarget Therapeutics, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
For detecting electrolytic separation of an occlusion device
US 5643254 A
Abstract
This invention is a method for ensuring for endovascular occlusion through the formation of thrombi in arteries, veins, aneurysms, vascular malformations, and arteriovenous fistulas. In particular, it deals with a method to predictably determine the instant of electrolytic detachment of an embolic device which is introduced to and is intended to remain at the desired thrombus formation site. The invention further includes a method for delivering an embolic device and detecting its electrolytic separation.
Images(12)
Previous page
Next page
Claims(21)
We claim as our invention:
1. A method for detecting electrolytic separation of an occlusion device comprising the steps of:
(a) providing a delivery member and an occlusion device coupled to the delivery member via a linking member;
(b) delivering the occlusion device to a desired site in a mammal via the delivery member;
(c) supplying DC power with a superposed AC signal to the linking member; and
(d) monitoring the superposed AC signal to detect a change in said signal.
2. The method of claim 1 wherein step (a) includes selecting the occlusion device to be a vasoocclusive coil.
3. The method of claim 2 wherein step (a) includes selecting the vasoocclusive coil to comprise a radiopaque physiologically compatible material.
4. The method of claim 3 wherein step (a) includes selecting the material from the group consisting of platinum, tungsten, gold, iridium and alloys thereof.
5. The method of claim 4 wherein steps (a) includes selecting the material to be platinum.
6. The method of claim 1 wherein step (c) includes selecting the DC power to provide a voltage in a range of about 0.1 to 6 volts.
7. The method of claim 1 wherein step (c) includes selecting the DC power to provide constant current in a range of about 0.1 to 10 milliamps.
8. The method of claim 1 wherein step (a) includes selecting the linking member to be stainless steel.
9. The method of claim 1 further including the step of interrupting the DC power supply to the linking member in response to detecting a sudden change in the superposed AC signal.
10. The method of claim 1 wherein the AC signal includes a voltage amplitude and step (d) comprises monitoring the voltage amplitude of the AC signal and further including the steps of averaging the monitored voltage amplitude over time to obtain an average monitored value and interrupting the DC power supply to the linking member when at least about a 20% change from the average monitored value is detected.
11. The method of claim 1 wherein step (c) includes providing a constant DC current with AC superposition to the linking member.
12. The method of claim 1 wherein step (a) includes selecting the linking member to have a conductivity that differs from that of the occlusion device.
13. The method of claim 1 wherein step (a) includes providing a linking member comprising stainless steel and the occlusion device to comprise a material selected from the group consisting of platinum, tungsten, gold, iridium and alloys thereof.
14. The method of claim 1 wherein step (a) includes selecting the delivery member to be a guidewire.
15. A method for detecting electrolytic separation of an occlusion device comprising the steps of:
(a) delivering an occlusion device, which is coupled to a delivery member via a linking member, to a desired site in a mammal via the delivery member;
(b) forming a circuit path including the linking member and occlusion device;
(c) supplying DC power with a superposed AC signal to said circuit path; and
(d) monitoring the AC impedance of said circuit path to detect a change in said impedance.
16. The method of claim 15 wherein said monitoring step includes monitoring the AC impedance of said circuit path to detect a change in said impedance indicative of separation between the occlusion device and linking member.
17. The method of claim 15 wherein the AC signal includes a voltage amplitude and step (d) comprises monitoring the voltage amplitude of the AC signal and further including the steps of averaging the monitored voltage amplitude over time to obtain an average monitored value and interrupting the DC power supply to the linking member when at least about a 20% change from the average monitored value is detected.
18. The method of claim 15 wherein the AC signal includes a voltage amplitude and said step (d) comprises monitoring the voltage amplitude of the AC signal and further including the step of interrupting the DC power supply to the linking member in response to detecting a predetermined change in the AC signal amplitude.
19. A method for detecting electrolytic separation of an occlusion device comprising the steps of:
(a) delivering an occlusion device, which is coupled to a delivery member via a linking member, to a desired site in a mammal via the delivery member;
(b) supplying DC power with a superposed AC signal to the linking member; and
(c) monitoring the superposed AC signal to detect a change therein indicative of separation between the occlusion device and delivery member.
20. The method of claim 19 wherein the AC signal includes a voltage amplitude and step (c) comprises monitoring the voltage amplitude of the AC signal and further including the step of interrupting the DC power supply to the linking member in response to detecting a predetermined change in the AC signal amplitude.
21. The method of claim 19 wherein the AC signal includes a voltage amplitude and step (d) comprises monitoring the voltage amplitude of the AC signal and further including the steps of averaging the monitored voltage amplitude over time to obtain an average monitored value and interrupting the DC power supply to the linking member when at least about a 20% change from the average monitored value is detected.
Description

This application is a continuation of application Ser. No. 08/205,512, filed Mar. 3, 1994, now abandoned.

FIELD OF THE INVENTION

This invention is a method for ensuring endovascular occlusion through the formation of mechanical blockage in arteries, veins, aneurysms, vascular malformations, and arteriovenous fistulas. In particular, it deals with a method to indicate predictably, the time of electrolytic separation of an endovascular device which has been introduced to and is intended to remain at the desired thrombus formation site.

BACKGROUND OF THE INVENTION

Approximately 25,000 intracranial aneurysms rupture each year in North America. The primary purpose of treatment for a ruptured intracranial aneurysm is to prevent rebleeding. There are a variety of ways to treat ruptured and non-ruptured aneurysms.

Possibly the most widely known of these procedures is an extravascular approach using surgery or microsurgery. This treatment is common with intracranial berry aneurysms. The method comprises a step of clipping the neck of the aneurysm, performing a suture ligation of the neck, or wrapping the entire aneurysm. Each of these procedures is formed by intrusive invasion into the body and performed from the outside of the aneurysm or target site. General anesthesia, craniotomy, brain retraction, and placement of a clip around the neck of the aneurysm are typically required in these surgical procedures. The surgical procedure is often delayed while waiting for the patient to stabilize medically. For this reason, many patients die from the underlying disease or defect prior to the initiation of the procedure.

Another procedure--the extra-intravascular approach--involves surgically exposing or stereotactically reaching an aneurysm with a probe. The wall of the aneurysm is then perforated from the outside and various techniques are used to occlude the interior in order to prevent it from rebleeding. The techniques used to occlude the aneurysm include electrothrombosis, adhesive embolization, hog hair embolization, and ferromagnetic thrombosis. These procedures are discussed in U.S. Pat. No. 5,122,136 to Guglielmi et al., the entirety of which is incorporated by reference.

A still further approach, the least invasive, is described in Guglielmi et al. It is the endovascular approach. In this approach, the interior of the aneurysm is entered by use of a catheter such as those shown in Engelson (Catheter Guidewire), U.S. Pat. No. 4,884,575 and also in Engelson (Catheter for Guidewire Tracking), U.S. Pat. No. 4,739,768. These patents describe devices utilizing guidewires and catheters which allow access to an aneurysm from remote portions of the body. Specifically, by the use of catheters having very flexible distal regions and guidewires which are steerable to the region of the aneurysm, embolic devices which may be delivered through the catheter are an alternative to the extravascular and extra-intravascular approaches.

The endovascular approach typically includes two major steps. The first step involves the introduction of the catheter to the aneurysm site using devices such as shown in the Engelson patents. The second step often involves filling the aneurysm in some fashion or another. For instance, a balloon may be introduced into the aneurysm from the distal portion of the catheter where it is inflated, detached, and left to occlude the aneurysm. In this way, the parent artery is preserved. Balloons are becoming less in favor because of difficulty in introducing the balloon into the aneurysm sac, the possibility of an aneurysm rupture due to overinflation of the balloon within the aneurysm or due to stress placed on the nonspherically shaped aneurysm by the spherical balloon, and the risk associated with traction produced when detaching the balloon.

A highly desirable embolism-forming device that may be introduced into an aneurysm using endovascular placement procedures, is found in U.S. Pat. No. 4,994,069, to Ritchart et al. The device--typically a platinum/tungsten alloy coil having a very small diameter--may be introduced into an aneurysm through a catheter such as those described in Engelson above. These coils are often made of wire having a diameter of 2-6 mils. The coil diameter may be 10-30 mils. These soft, flexible coils may be of any length desirable and appropriate for the site to be occluded. For instance, the coils may be used to fill a berry aneurysm. Within a short period of time after the filling of the aneurysm with the embolic device, a thrombus forms in the aneurysm and is shortly hereafter complemented with a collagenous material which significantly lessens the potential for aneurysm rupture.

Coils such as seen in Ritchart et al. may be delivered to the vasculature site in a variety of ways including, e.g., mechanically detaching them from the delivery device as is shown in U.S. Pat. No. 5,250,071, to Palermo or by electrolytic detachment as is shown in Guglielmi et al. (U.S. Pat. No. 5,122,136), discussed above.

Guglielmi et al. shows an embolism-forming device and procedure for using that device. Specifically, the Guglielmi device fills a vascular cavity (such as an aneurysm) with an embolic device, typically a platinum coil, that has been endovascularly delivered. The coil is then severed from its insertion tool by the application of a small electric current. Desirably, the insertion device involves a guidewire which is attached at its distal end to the embolic device by a sacrificial joint that is electrolytically dissolvable. Guglielmi et al. suggests that when the embolic device is a platinum coil, the platinum coil may be 1-50 cm. or longer as is necessary. Proximal of the embolic coil is a guidewire, often stainless steel in construction. The guidewire is used to push the platinum embolic coil, obviously with great gentleness, into the vascular site to be occluded. The patent shows a variety of ways of linking the embolic coil to the pusher guidewire. For instance, the guidewire is tapered at its distal end and the distal tip of the guidewire is soldered into the proximal end of the embolic coil. Additionally, a stainless steel coil is wrapped coaxially about the distal tapered portion of the guidewire to provide column strength to the guidewire. This coaxial stainless steel wire is joined both to the guidewire and to the embolic coil. Insulation may be used to cover a portion of the strength-providing stainless steel coil. This arrangement provides for two regions which must be electrolytically severed before the embolic coil is severed from the guidewire.

U.S. patent application Ser. No. 08/147,529 filed Nov. 3, 1993, describes a variation of the Guglielmi detachable coil using an improved sacrificial link between the guidewire and the coil. The size of the sacrificial link is limited to allow more precise placement of the embolic device and facile, quick detachment. The focussed electrolysis found at the sacrificial site reduces the overall possibility of occurrence of multiple electrolysis sites and liberation of large particles from those sites.

The present invention is a method for detecting the detachment of the endovascular devices described above so that the power supply can be shut down immediately following detachment.

SUMMARY OF THE INVENTION

The present invention is a method for detecting electrolytic separation of an endovascular occlusion device. The method involves monitoring the voltage applied to the endovascular device via a constant current circuit through the human patient, detecting a time-averaged drop in the monitored voltage upon separation of the occlusion device, and shutting down the voltage when the time-averaged voltage drop is greater than about 20%.

In a further aspect, the invention is a method for delivering an endovascular occlusion device. The method involves inserting a guidewire with a distal, discrete, sacrificial line susceptible to electrolytic disintegration in blood. A power supply attached to the guidewire is turned on and delivers a positive electric current. A voltage drop is detectable when the sacrificial link has been severed and the power supply is shut down.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a block diagram showing the method for detecting the electrolytic separation of an endovascular occlusion device.

FIG. 2 shows a sideview of an electrolytically susceptible, sacrificial link between a core wire and an embolic device, the electrolytic separation of which is detectable by the inventive method.

FIG. 3 shows side view of a typical assembly useful in the inventive method.

FIGS. 4 and 5 schematically depict the method for deploying a vasoocclusive device using the inventive method.

FIG. 6 is a block diagram showing the system architecture for delivery of the embolic device.

FIG. 7 is a circuit diagram showing the system electronics for monitoring delivery of the embolic device.

FIGS. 8A and 8B show a table of data from a detachment time study using the ON PCDC power supply.

DESCRIPTION OF THE INVENTION

The method of the present invention is shown schematically in FIG. 1. A constant current feedback loop 310 and an embolic device detection circuit (EDDC) 319 are shown. Such circuit provides for accurate detection of the separation of the device from a guidewire. Operation of the circuit is described below. The method for detecting electrolytic separation of the embolic devices may be used with the devices shown in U.S. Pat. No. 5,122,136 to Guglielmi et al., the entirety of which patent is incorporated by reference.

Electrolytic separation of a device from a guidewire may be facilitated by means of the assembly 100 shown in FIG. 2. The assembly 100 is made up generally of a guidewire 102 which tapers at its distal end to a point and is soldered into the proximal end of a vasoocclusive device 104, which in this case is a coil and is of a radiopaque physiologically compatible material such as platinum, tungsten, gold, iridium or alloys of these. All of the guidewire 102 is covered with an insulating material such as TeflonŽ, polyurethane, polyethylene, polypropylene, or other suitable polymeric material, except the most distal exposed joint or sacrificial link 106. Link 106 is not coated with an electrical insulator and is of a material which is susceptible to electrolytic dissolution in blood such as stainless steel. The core wire 102 is typically stainless steel and may be disposed within a protective catheter not shown. Stainless steel guidewire 102 typically is approximately 10-30 mils. in diameter. Often the guidewire is 50-300 cm. in length, that is to say, from the entry site outside the body to sacrificial link 106.

Sacrificial link 106 is a discrete link. By "discrete" we mean to say preferably that the joint is substantially dissolved upon release of the vasoocclusive device 104. Alternatively, "discrete" may mean that the length of the link 106 is no greater than the diameter of the sacrificial link 106 or that the electrolytic surface present after the vasoocclusive device is released is not substantially greater than would be a circle having the diameter of the sacrificial link 106.

Also shown in FIG. 2 is a coil 108 which is soldered at its proximal end and, typically, is designed to provide some column strength to the guidewire assembly while not detrimentally affecting the flexibility of the tapered portion of the guidewire 102. Obviously, in the area where the support coil 108 is soldered to guidewire 102, the coating on 102 is not present, allowing the solder to adhere to metal surfaces. Further, on the distal tip of core wire 102 may be found a pair of insulators: sleeve 110 and end plug 112 which serve to further remove the stainless steel coil 108 from contact with the blood while the step of electrolytic detachment is carried out. Preferably, the end plug 112 and sleeve 110 are adhesively attached to each other to form an electrically insulating or electrolysis-tight housing about coil 108. The end plug 112 and sleeve 110 form a planar surface in the Figure which is generally planar and perpendicular to the axis of the core wire 102. The shape of the surface is not critical except to the extent it allows reasonably free access of the blood to the sacrificial link 106. Curved, slotted, and other variations of the end surface are also contemplated in this invention.

As noted above, the distal end of the guidewire 102 is inserted into the solder joint 114 forming the proximal end of vasoocclusive device 104.

As will be discussed in more detail below, the discrete sacrificial link 106 is completely or substantially completely dissolved during electrolysis.

Vasoocclusive device 104 is shown to be a coil. It may be a coil or a braid or other vasoocclusive device as is already known. The vasoocclusive device may be covered or connected with fibrous materials tied to the outside of the coil or braided onto the outer cover of the coil as desired. Such fibrous adjuvants may be found in U.S. patent application Ser. No. 07/965,973, to Phelps et al, or in U.S. patent application Ser. No. 07/771,013, entitled "Vasoocclusion Coil with Attached Fibrous Elements", the entirety of which are incorporated by reference.

FIG. 3 shows a typical layout involving the inventive discrete sacrificial link 106 as was generally shown in FIG. 2 above. In FIG. 3, a somewhat conventional TeflonŽ laminated or similarly insulated stainless steel guidewire 102 may be placed within a protective catheter. As was noted above, stainless steel guidewire 102 may have a diameter of approximately 10-30 mils. In the embodiment illustrated in FIG. 3, guidewire assembly 140 is shown as including guidewire 102, which is tapered at its distal end to form a conical section 142 which joins a further section 144 that extends along a length of the guidewire designated with reference numeral 146. Section 144 then gradually narrows down to a thinner section 148. The guidewire assembly 140, as noted above, may be placed within a catheter body and is typically 50-200 cm. in length down to sacrificial link 106. As was shown in FIG. 2, the distal section of guidewire assembly 140 has an outer TeflonŽ sleeve 110' (or sleeve of other appropriate insulating material) which is shown somewhat longer than the sleeve 110 in FIG. 2. Furthermore, it has an end plug 112 to permit isolation of the guidewire electrically from the blood except at sacrificial discrete link 106. The proximal end of vasoocclusive device 104 is typically a soldered tip or a joint 114. Preferably, vasoocclusive device 104, when a coil, forms a secondary loop after it emanates from the end of the catheter. The distal end of vasoocclusive device 104 may also have an end plug or tip 154 to prevent punctures of the aneurysm when introduced into the aneurysm sac.

Coil or vasoocclusive device 104 may be pre-biased to form a cylinder or conical envelope. However, the vasoocclusive device 104 is extremely soft and its overall shape is easily deformed. When inserted within the catheter (not shown), the vasoocclusive device 104 is easily straightened to lie axially within the catheter. Once ejected from the tip of the catheter, vasoocclusive device 104 may form a shape shown in FIG. 3 or may be loosely deformed to conform to the interior shape of the aneurysm.

FIG. 4 shows the placement of the inventive devices described above within a vessel 156 with the tip of catheter 158 placed near neck 160 of aneurysm 162. A vasooclusive device, such as device 104 (FIG. 4) is fed into aneurysm 162 at least until sacrificial link 106 is exposed beyond the distal tip of the catheter 158. A positive electric current of approximately 0.01-10 milliamps, preferably about 1 milliamp, at 0.1-6 volts, is applied to guidewire 102 to form a thrombus within aneurysm 162. The negative pole 168 of power supply 170 is typically placed in electrical contact with the skin.

After the thrombus has been formed and the aneurysm occluded, vasoocclusive device 104 is detached from guidewire 102 by electrolytic disintegration of sacrificial link 106.

After sacrificial link 106 is completely dissolved by electrolytic action, typically within 3-10 minutes, the guidewire 102, catheter 158, are removed from vessel 156, leaving aneurysm 162 occluded as shown in FIG. 5.

The process is typically practiced under fluoroscopic control with local anesthesia. A transfemoral catheter is utilized to treat a cerebral aneurysm and is usually introduced at the groin. The physician guides the distal tip of the catheter to the target site. The embolic device is then inserted into the catheter. Using a fluoroscope, the physician guides the device to the desired position before separation is initiated. When the vasoocclusive device 104 is platinum, it is not effected by electrolysis. When the guidewire and pertinent portions of the supporting coils at the distal tip of the guidewire are adequately coated with insulating coverings, only the exposed portion at the sacrificial link 106 is effected by the electrolysis.

The positive terminal of the power supply is attached to the proximal end of the guidewire. A needle with a ground wire attached is connected between the negative terminal of the power supply and the opposite thigh of the patient. Alternatively, a ground wire with a skin patch located behind the shoulder of the patient may be used.

Power is supplied via terminals marked plus (+) and minus (-) on microcontroller 300 as shown in FIG. 6. A DC current of between about 0.1 and 10 milliamps at 0.1 to 6 volts is sent through the embolic device and patient. The voltage display 302 is a three digit red LED readout that displays the voltage required to maintain the current flowing through the coil and the patient. The fixed-decimal display shows voltages from 0.00 to 9.99 volts DC. In Pause Mode, that is, when electrolytic separation has occurred, the display shows the voltage immediately prior to coil detachment. The current display 303 is a three digit red LED readout that displays the actual current flowing through the coil and the patient. The fixed-decimal display shows current from 0.00 to 1.25 mA DC. In addition, the display briefly flashes the new current setting when the front panel current select switch is pressed or when power-up occurs, and then returns to the continuous display of actual current. In Pause Mode, the display shows the current immediately prior to coil detachment. The current may be changed by the physician at any time. In Normal Mode, the current-select switch 308 is used to change the current setting. When the power supply is turned on, the current is automatically set to 1.00 milliamps. Pressing the current-select switch one time changes the setting to 0.50 milliamps, pressing it a second time changes it to 0.75 milliamps and pressing it a third time returns the setting to 1.00 milliamps. Each time the switch is pressed, the current display 303 briefly flashes the new current setting. In Pause Mode, pressing the current-select switch 308 will resume Normal Mode. The current and voltage displays 303 and 302 resume the real-time display of these parameters and the elapsed time display 304 resumes counting from where it was paused.

The current flowing through the embolic device initiates electrolysis near the junction between the embolic device, in this case the platinum coil and the guidewire. Over a period of several minutes, the electrolysis dissolves the exposed steel and the embolic device detaches completely from the guidewire. The elapsed time display 304, a four digit red LED readout, displays the elapsed time in minutes and seconds from the start of the procedure. The flashing colon display shows elapsed time from 00:00 to 59:59. The check indicator 305, a yellow LED indicator turns on when the microprocessor and EDDC electronics determine that coil detachment has occurred, and indicates that the power supply has entered Pause Mode. The detach indicator 306 flashes when the power supply is in Pause Mode after detecting a coil detachment. In each case, the physician is instructed to check detachment using fluoroscopy. In Pause Mode, the display shows the time required to detach the coil.

The CPU 300 in this case is a Motorola MC68HC811E2FN single-chip microcontroller with 2048 bytes of EEPROM, 256 bytes of RAM, an 8 channel 8-bit A/D converter, and three 8-bit I/O port controls and monitors vital functions of the power supply. Other similar microprocessors may be useful in the inventive method as well. The CPU 300 is responsible for monitoring input battery voltage, output (coil) voltage and current, elapsed time and requests for changing the coil current. The CPU is outside the critical path of the current control loop, which is implemented in hardware. The CPU manages the LED displays, status indicators and beeper, runs self-diagnostic tests at power-on, issues current setting changes and the fail-safe current enable signal, monitors the EDDC signal to determine when coil detachment has occurred, monitors the current-select switch, and communicates with a PC during programming.

The constant current feedback loop 310 monitors an error-correction voltage required to maintain the steady current through the patient. The embolic device detection circuit 319, a feedback loop, identifies separation of the embolic device, as reflected in changes in the amplitude of the error correction voltage from the constant-current source. The error correction voltage signal is amplified 320 and rectified 321 by the embolic device detection circuit (EDDC) and is then sent to the CPU for analysis.

The construction of the EDDC is shown in FIG. 7. It is desired to maintain the output of amplifier 330 at a constant current. Amplifier 330 is preferably a National Semiconductor LMC660CN. This device was chosen because of its ability to operate on a single (positive) power supply and because it has a high voltage gain of 126 decibels (dB) and a Gain Bandwidth Product of 1.4 Megahertz (MHz). When the constant current amplifier 330 has achieved equilibrium--when the output current exactly matches the setpoint present at the non-inverting input terminal--the amplifier will oscillate at approximately 20 to 24 kilohertz (kHz) at an amplitude of several hundred millivolts due to a lagging error correction signal (out-of-phase feedback). Thus, the amplifier delivers constant DC current with AC superposition. The amplitude of this signal is dependent on the band-width characteristics of the constant current amplifier and the impedance of the steel and the platinum coils and of the patient's body. Capacitor 344, a 4.7 microfarad tantalum capacitor, is used to reduce the amplitude of the self-oscillation voltage to between about 40 to 60 millivolts AC while maintaining a rapid DC response.

Accordingly, a reference voltage 333 is held constant, in this case from 0.166 to 0.332 volts. These voltages represent a constant current output of between 0.5 and 1 milliamp. Resistor 342, with a resistance in this instance of 332 ohms, is connected between the inverting input terminal of amplifier 330 and ground and ensures the maintenance of the constant current flow from amplifier 330.

The constant current flowing out of amplifier 330 flows through the patient's body and the embolic device as described previously. The resistance of the patient's body is often in the range of 1000 to 4000 ohms, with 3300 ohms being typical.

In the EDDC, the AC feedback signal generated when the current flows through the patient's body is selectively passed through capacitor 340, in this case, a 0.1 microfarad monolithic capacitor. The AC signal is then amplified in the AC signal amplifier 320, rectified in the AC to DC rectifier 321 and the resulting DC signal is further amplified in DC amplifier 322. The amplified DC signal, the level of which is representative of the amplitude of the error correction voltage of constant current amplifier 330 is then sent to the microprocessor (CPU) 300 for analysis as described below.

By monitoring the level of the amplified DC signal every 10 to 250 milliseconds, preferably every 50 to 200 milliseconds, and constantly averaging the signal every 5 to 50 samples, preferably every 10-20 samples or every 0.5-10 seconds, preferably every 2-6 seconds, the CPU can accurately determine the instant the embolic device detaches. When the embolic device detaches, constant current amplifier 330 is no longer in equilibrium and instantly reacts to the change in impedance. During the next several dozen milliseconds, amplifier 330 makes large corrections to the DC output voltage to maintain the set current, which disrupts the stable self-oscillation feedback. During this period the amplified EDDC signal will show a sudden voltage drop of greater than 10%, preferably a drop of greater than 20% of the average level for the procedure. This sudden voltage drop reliably detects the dissolution of the junction between the embolic device and the guidewire. Previous methods relied simply on the increase in impedance upon coil detachment. When the sudden voltage drop is detected, the microprocessor immediately halts current flow, energizes the patient isolation relay, freezes the voltage, current and time displays, and emits five beeps to indicate to the physician that coil detachment has occurred. When the power supply is in this "Pause Mode" no further electrolysis can occur. Using fluoroscopy, the physician can verify that detachment has occurred. If detachment is incomplete and further electrolysis is necessary, the procedure can be resumed by pressing the current-select switch on the front panel. If detachment is verified, the physician can turn off the power supply and withdraw the guidewire. If necessary, another coil can be placed at the site and the power supply started again. If no action is taken, the power supply will automatically turn itself off after 15 minutes.

The following Example is intended to illustrate but not to limit the invention in any manner.

EXAMPLE

Detachment time studies were run in a preclinical setting using the Guglielmi Detachable Coil (GDC) as described in Guglielmi et al. with the inventive detection system (see Table I). Thirty pigs were anesthetized and catheterized such that a platinum coil was positioned inside the internal carotid artery. The time of coil detachment was determined using the EDDC. For 28 of the samples, at time 0, the 1 milliamp of power was supplied, for one sample 0.5 milliamps of power was supplied and for one sample 0.75 milliamps of power was supplied. The constant current circuit was monitored as was the embolic device detection circuit. As reflected in Table I, detachment occurred in all cases within 6 minutes of supplying power supply and the majority of detachments occurred within 2 minutes.

The inventive electrolytic separation detection method has been described with reference to a platinum coil and stainless steel sacrificial link for the purposes of illustration of a particular embodiment of the invention and should not be taken as limiting the invention. Many alterations and modifications may be made by those having ordinary skill in the art without departing from the spirit and scope of the invention as defined by the following claims.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4057063 *Feb 27, 1976Nov 8, 1977U.S. Philips CorporationDevice for sterilization by transuterine tube coagulation
US4416276 *Oct 26, 1981Nov 22, 1983Valleylab, Inc.Adaptive, return electrode monitoring system
US4739768 *Jun 2, 1986Apr 26, 1988Target TherapeuticsCatheter for guide-wire tracking
US4884579 *Apr 18, 1988Dec 5, 1989Target TherapeuticsCatheter guide wire
US4994069 *Nov 2, 1988Feb 19, 1991Target TherapeuticsVaso-occlusion coil and method
US5122136 *Mar 13, 1990Jun 16, 1992The Regents Of The University Of CaliforniaEndovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
US5167658 *Jan 31, 1991Dec 1, 1992Mdt CorporationMethod and apparatus for electrosurgical measurement
US5170802 *Jan 7, 1991Dec 15, 1992Medtronic, Inc.Implantable electrode for location within a blood vessel
US5190517 *Jun 6, 1991Mar 2, 1993Valleylab Inc.Electrosurgical and ultrasonic surgical system
US5250071 *Sep 22, 1992Oct 5, 1993Target Therapeutics, Inc.Detachable embolic coil assembly using interlocking clasps and method of use
US5300068 *Apr 21, 1992Apr 5, 1994St. Jude Medical, Inc.Electrosurgical apparatus
US5304194 *Oct 2, 1992Apr 19, 1994Target TherapeuticsVasoocclusion coil with attached fibrous element(s)
US5341807 *Jun 30, 1992Aug 30, 1994American Cardiac Ablation Co., Inc.Ablation catheter positioning system
US5354295 *Feb 24, 1992Oct 11, 1994Target Therapeutics, Inc.In an endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
US5423810 *Feb 25, 1993Jun 13, 1995G2 Design LimitedCauterising apparatus
Non-Patent Citations
Reference
1Becker et al., "Long-term occlusion of the porcine cystic duct by means of endoluminal radio-frequency electrocoagulation" Radiology (1988) 167:63-68.
2 *Becker et al., Long term occlusion of the porcine cystic duct by means of endoluminal radio frequency electrocoagulation Radiology (1988) 167:63 68.
3Kopecky et al., "Percutaneous transdermal endoureteral radio-frequency electrocautery for occlusion: Case report" Radiology (1989) 170:1047-1048.
4 *Kopecky et al., Percutaneous transdermal endoureteral radio frequency electrocautery for occlusion: Case report Radiology (1989) 170:1047 1048.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5800426 *May 16, 1996Sep 1, 1998Kabushiki Kaisha Tokai Rika Denki Seisakush.High-frequency heating power device for catheter
US5935148 *Jun 24, 1998Aug 10, 1999Target Therapeutics, Inc.Detachable, varying flexibility, aneurysm neck bridge
US6063104 *May 18, 1999May 16, 2000Target Therapeutics, Inc.Detachable, varying flexibility, aneurysm neck bridge
US6090125 *Jun 2, 1998Jul 18, 2000Musc Foundation For Research DevelopmentAnatomically shaped vasoocclusive device and method of making the same
US6102932 *Dec 15, 1998Aug 15, 2000Micrus CorporationIntravascular device push wire delivery system
US6136015 *Aug 25, 1998Oct 24, 2000Micrus CorporationVasoocclusive coil
US6149664 *Aug 27, 1998Nov 21, 2000Micrus CorporationShape memory pusher introducer for vasoocclusive devices
US6156061 *Aug 29, 1997Dec 5, 2000Target Therapeutics, Inc.Fast-detaching electrically insulated implant
US6168592 *Apr 23, 1999Jan 2, 2001Target Therapeutics, Inc.Aneurysm closure device assembly
US6168615May 4, 1998Jan 2, 2001Micrus CorporationMethod and apparatus for occlusion and reinforcement of aneurysms
US6171326Aug 27, 1998Jan 9, 2001Micrus CorporationThree dimensional, low friction vasoocclusive coil, and method of manufacture
US6221066Mar 9, 1999Apr 24, 2001Micrus CorporationShape memory segmented detachable coil
US6293960May 22, 1998Sep 25, 2001Micrus CorporationCatheter with shape memory polymer distal tip for deployment of therapeutic devices
US6306153Apr 25, 2000Oct 23, 2001Micrus CorporationVasoocclusive coil
US6319267Jul 25, 2000Nov 20, 2001Micrus CorporationIntravascular device push wire delivery system
US6342063Jan 26, 2000Jan 29, 2002Scimed Life Systems, Inc.Device and method for selectively removing a thrombus filter
US6344041Oct 26, 2001Feb 5, 2002David KupieckiAneurysm closure device assembly
US6383204Dec 15, 1998May 7, 2002Micrus CorporationVariable stiffness coil for vasoocclusive devices
US6397850 *Feb 9, 2000Jun 4, 2002Scimed Life Systems IncDual-mode apparatus and method for detection of embolic device detachment
US6409721Mar 10, 2000Jun 25, 2002Target Therapeutics, Inc.Process for forming an occlusion in a body cavity
US6416530 *Jul 12, 2001Jul 9, 2002Scimed Life Systems, Inc.Device and method for selectively removing a thrombus filter
US6425914Sep 21, 2000Jul 30, 2002Target Therapeutics, Inc.Fast-detaching electrically insulated implant
US6551305Mar 19, 2001Apr 22, 2003Micrus CorporationShape memory segmented detachable coil
US6558377Jan 9, 2001May 6, 2003Kyu-Ho LeeEmbolic material detachment detection system and method and assembly for embolic treatments
US6589236Feb 28, 2002Jul 8, 2003E. Thomas WheelockAssembly containing an electrolytically severable joint for endovascular embolic devices
US6599299Jun 26, 2001Jul 29, 2003Leonard S. SchultzDevice and method for body lumen occlusion
US6638293Jan 31, 1997Oct 28, 2003Transvascular, Inc.Methods and apparatus for blocking flow through blood vessels
US6656201Nov 15, 2001Dec 2, 2003Micrus CorporationVariable stiffness coil for vasoocclusive devices
US6679903Oct 3, 2001Jan 20, 2004Micrus CorporationIntravascular device push wire delivery system
US6872218Nov 10, 2003Mar 29, 2005Micrus CorporationVariable stiffness coil for vasoocclusive devices
US6936055Mar 10, 2000Aug 30, 2005Scime Life Systems, Inc.Detachable aneurysm neck bridge (III)
US6953473Dec 20, 2001Oct 11, 2005Boston Scientific Scimed, Inc.Detachable device with electrically responsive element
US7070608Oct 2, 2001Jul 4, 2006Micrus CorporationVasoocclusive coil
US7147618Dec 8, 2003Dec 12, 2006Micrus Endovascular CorporationIntravascular device push wire delivery system
US7303571Aug 29, 2003Dec 4, 2007Medtronic Vascular, Inc.Methods and apparatus for blocking flow through blood vessels
US7651521Nov 18, 2004Jan 26, 2010Cardiomind, Inc.Corewire actuated delivery system with fixed distal stent-carrying extension
US7699884Mar 22, 2006Apr 20, 2010Cardiomind, Inc.Method of stenting with minimal diameter guided delivery systems
US7763037Mar 18, 2005Jul 27, 2010Castlewood Surgical, Inc.System and method for attaching a vein, an artery, or a tube in a vascular environment
US7771463Nov 2, 2005Aug 10, 2010Ton Dai TTwist-down implant delivery technologies
US7785361Mar 23, 2004Aug 31, 2010Julian NikolchevImplant delivery technologies
US7789915May 14, 2007Sep 7, 2010Vance Products IncorporatedStent for implantation
US7862602Dec 20, 2005Jan 4, 2011Biosensors International Group, LtdIndirect-release electrolytic implant delivery systems
US7955343Oct 26, 2007Jun 7, 2011Medtronic Vascular, Inc.Methods and apparatus for blocking flow through blood vessel
US8016853May 3, 2005Sep 13, 2011Boston Scientific Scimed, Inc.Sacrificial anode stent system
US8016869Dec 24, 2003Sep 13, 2011Biosensors International Group, Ltd.Guidewire-less stent delivery methods
US8157855Dec 5, 2003Apr 17, 2012Boston Scientific Scimed, Inc.Detachable segment stent
US8177809Sep 4, 2009May 15, 2012Curaseal Inc.Inflatable device for enteric fistula treatment
US8206416Sep 28, 2009Jun 26, 2012Curaseal Inc.Inflatable device for enteric fistula treatment
US8221451Sep 28, 2009Jul 17, 2012Curaseal Inc.Inflatable device for enteric fistula treatment
US8273116Nov 30, 2010Sep 25, 2012Biosensors International Group, Ltd.Indirect-release electrolytic implant delivery systems
US8328860Feb 27, 2008Dec 11, 2012Covidien LpImplant including a coil and a stretch-resistant member
US8377094Sep 26, 2011Feb 19, 2013Curaseal Inc.Enteric fistula treatment devices
US8377112Sep 7, 2011Feb 19, 2013Boston Scientific Scimed, Inc.Sacrificial anode stent system
US8388650Sep 4, 2009Mar 5, 2013Pulsar Vascular, Inc.Systems and methods for supporting or occluding a physiological opening or cavity
US8444666Sep 12, 2003May 21, 2013Cook Medical Technologies LlcRetrievable filter
US8486094Aug 21, 2007Jul 16, 2013Castlewood Surgical, Inc.System and method for providing an obturator for enhanced directional capabilities in a vascular environment
US8535345Oct 7, 2004Sep 17, 2013DePuy Synthes Products, LLCVasoocclusive coil with biplex windings to improve mechanical properties
US8545530Jan 3, 2006Oct 1, 2013Pulsar Vascular, Inc.Implantable aneurysm closure systems and methods
US8551132Apr 19, 2007Oct 8, 2013Pulsar Vascular, Inc.Methods and systems for endovascularly clipping and repairing lumen and tissue defects
US8579954Jan 27, 2006Nov 12, 2013Biosensors International Group, Ltd.Untwisting restraint implant delivery system
US8657870Jun 26, 2009Feb 25, 2014Biosensors International Group, Ltd.Implant delivery apparatus and methods with electrolytic release
US8728101Nov 18, 2008May 20, 2014Castlewood Surgical, Inc.System and method for providing an obturator for enhanced directional capabilities in a vascular environment
US8740970Dec 2, 2009Jun 3, 2014Castlewood Surgical, Inc.System and method for attaching a vessel in a vascular environment
US8758376Sep 22, 2008Jun 24, 2014Castlewood Surgical, Inc.System and method for attaching a vein, an artery, or a tube in a vascular environment
US20120130461 *Apr 28, 2010May 24, 2012Medtronic, Inc.Radiopaque markers for implantable medical leads, devices, and systems
USRE42758Nov 10, 2006Sep 27, 2011Micrus CorporationExpandable curvilinear strut arrangement for deployment with a catheter to repair an aneurysm
USRE43311Feb 14, 2007Apr 10, 2012Stryker CorporationFast-detaching electrically insulated implant
CN101365401BAug 29, 2006Oct 5, 2011卡迪欧曼德股份有限公司Indirect-release electrolytic implant delivery systems
CN101605509BDec 14, 2007Sep 19, 2012生物传感器国际集团有限公司Stent systems
EP2340790A1Aug 29, 2006Jul 6, 2011Cardiomind, Inc.Indirect-release electrolytic implant delivery systems
EP2490764A2 *Oct 20, 2010Aug 29, 2012Thomas J. WolfeElectromagnetic thrombus treatment system and method
WO1999018852A1Oct 15, 1998Apr 22, 1999Ronald L ArensonMagnetically directable remote guidance systems, and methods of use thereof
WO2001058365A1Feb 6, 2001Aug 16, 2001Scimed Life Systems IncMethod for detecting separation of a vasoocclusion device
WO2002007606A1 *Dec 28, 2000Jan 31, 2002Lee Kyu HoEmbolic material detachment detection system and method and assembly for embolic treatments
WO2007055780A2 *Aug 29, 2006May 18, 2007Frank P BeckingIndirect-release electrolytic implant delivery systems
Classifications
U.S. Classification606/32, 606/41, 606/191
International ClassificationA61B17/00, A61B17/12, A61B18/12
Cooperative ClassificationA61B17/12145, A61B2017/00123, A61B17/12113, A61B17/12022, A61B2017/12063, A61B2017/00026, A61B18/1206
European ClassificationA61B17/12P5B1, A61B17/12P7C1, A61B17/12P
Legal Events
DateCodeEventDescription
Mar 15, 2011ASAssignment
Effective date: 20110103
Owner name: STRYKER NV OPERATIONS LIMITED, IRELAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TARGET THERAPEUTICS, INC.;REEL/FRAME:025957/0313
Owner name: STRYKER CORPORATION, MICHIGAN
Dec 19, 2008FPAYFee payment
Year of fee payment: 12
Dec 3, 2004FPAYFee payment
Year of fee payment: 8
Dec 28, 2000FPAYFee payment
Year of fee payment: 4
Dec 30, 1997CCCertificate of correction